Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Soft tissue sarcoma in adults

W C Mertens1, V H Bramwell

  • 1Department of Medical Oncology, London Regional Cancer Centre, Ontario, Canada.

Current Opinion in Oncology
|July 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial.

Breast cancer research and treatment·2011
Same author

Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.

Journal of the National Cancer Institute·2009
Same author

Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline.

Sarcoma·2008
Same author

The functional and clinical roles of osteopontin in cancer and metastasis.

Current molecular medicine·2002
Same author

A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma.

European journal of cancer (Oxford, England : 1990)·2001
Same author

Adjuvant chemotherapy for adult soft tissue sarcoma: Is there a standard of care?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Recent advancements in sarcoma staging have improved prognostic factor identification. While adjuvant therapy shows little progress, intensive chemotherapy for advanced sarcomas has increased response rates, potentially guiding future early-stage treatment studies.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Localized sarcomas require accurate staging for effective treatment planning.
  • Adjuvant therapy for sarcomas has seen limited recent advancements.
  • Advanced sarcoma treatment necessitates innovative therapeutic strategies.

Purpose of the Study:

  • To review recent improvements in prognostic factor delineation and staging of localized sarcomas.
  • To assess progress in adjuvant therapy for sarcomas.
  • To explore new therapeutic approaches for advanced sarcomas.

Main Methods:

  • Literature review of recent studies on sarcoma staging and prognostic factors.
  • Analysis of current adjuvant therapy efficacy.
  • Evaluation of novel chemotherapy regimens for advanced disease.

Related Experiment Videos

Main Results:

  • Improved methods for delineating prognostic factors and staging localized sarcomas have been reported.
  • Limited progress has been made in improving adjuvant therapy efficacy.
  • Dose-intensive chemotherapy regimens with colony-stimulating factor support show improved response rates in advanced sarcomas.

Conclusions:

  • Enhanced staging and prognostic factor identification aid in localized sarcoma management.
  • New chemotherapy strategies for advanced sarcomas show promise and may inform future early-stage trial designs.